# YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis

> **NCT06048588** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beijing Inno Medicine Co., Ltd.** · enrollment: 144 (actual)

## Conditions studied

- Atherosclerotic Cardiovascular Disease

## Interventions

- **DRUG:** YN001
- **DRUG:** Placebo for YN001
- **DRUG:** rosuvastatin calcium tablets

## Key facts

- **NCT ID:** NCT06048588
- **Lead sponsor:** Beijing Inno Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-08
- **Primary completion:** 2025-04-27
- **Final completion:** 2025-04-27
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2025-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06048588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06048588, "YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06048588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*